Galectin Therapeutics (GALT) Return on Assets (2011 - 2026)

Galectin Therapeutics' Return on Assets history runs 16 years deep, the most recent figure standing at 0.01% for Q1 2026.

• On a quarterly basis, Return on Assets rose 2.0% year-over-year to 0.01% in Q1 2026; TTM through Mar 2026 was 0.01%, a 2.0% increase from a year earlier, with the FY2025 full-year figure at 0.06%, changed 0.0% from the prior year.
• Return on Assets advanced to 0.01% in Q1 2026 per GALT's latest filing, from 0.02% in the prior quarter.
• Across five years, Return on Assets topped out at 0.01% in Q1 2022 and bottomed at 0.03% in Q1 2025.
• The 5-year median for Return on Assets is 0.02% (2024), against an average of 0.02%.
• Across the five-year window, Return on Assets declined 1 bps in 2022 and climbed 2 bps in 2026, its largest moves.
• Year by year, Return on Assets stood at 0.02% in 2022, then grew by 17 bps to 0.02% in 2023, then dropped by 8 bps to 0.02% in 2024, then climbed by 7 bps to 0.02% in 2025, then climbed by 20 bps to 0.01% in 2026.
• Per Business Quant, the three latest GALT Return on Assets figures stand at 0.01% (Q1 2026), 0.02% (Q4 2025), and 0.02% (Q3 2025).